Table 1.
Summary of published trials of anti-CD19 immunotherapies of B-ALL
| Agent | Population | N | CR rate (%) | Comment | Enrolled patients with MRD only? | sCRS | sCNS | Reference |
|---|---|---|---|---|---|---|---|---|
| Blinatumomab | Ph−, primary R/R ALL adult patients | 189 | 43 | Phase 2 | Not reported | 2% | 13% | 26 |
| Blinatumomab | Adults >65 R/R B-ALL | 261 | 47 | No response difference based on age >65 vs <65 y | Not reported | 5 | 41 | 12 |
| Blinatumomab | Pediatric R/R ALL | 31 | 31 | Phase 2 | Unknown | 5 | 5 | |
| Blinatumomab | Pediatric R ALL | 9 | 44 | CR reported for primary response (1 cycle) | Unknown | 22 | 33 | 4 |
| Blinatumomab | Adults, primary R/R ALL | 36 | 69 | Phase 2 | No | <1 | 17 | 27 |
| CAR-T 4-1BB | Children and adults, R/R ALL | 30 | 90 | Yes | 27 | 43 | 21 | |
| CAR-T CD28 | Children R/R ALL | 20 | 70 | Yes | 29 | <1 | 3 | |
| CAR-T CD28 | R/R B-ALL | 16 | 88 | Yes | 44 | 31 | 8 | |
| CAR-T 4-1BB | Adults R/R B-ALL | 29 | 93 | Yes | 23 | 50 | 28 | |
| CAR-T | Adults R/R B-ALL | 32 | 91 | Yes | 22 | 29 | ||
| CAR-T | Pediatric R/R B-ALL | 37 | 91 | Unknown | 30 | |||
| CAR-T 4-1BB (humanized) | Pediatric R/R B-ALL | 6 | 50 | Unknown | 31 |
MRD, minimal residual disease; R/R, relapsed/refractory; sCNS, severe neurologic adverse events, grade 3 or above; sCRS, severe cytokine release syndrome, grade 3 or above.